Tumor mutational burden and response rate to PD-1 inhibition
M Yarchoan, A Hopkins, EM Jaffee - New England Journal of …, 2017 - Mass Medical Soc
M Yarchoan, A Hopkins, EM Jaffee
New England Journal of Medicine, 2017•Mass Medical SocTumor Mutational Burden and Response Rate to PD-1 Inhibition | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced
Search SEARCH SPECIALTIES Cardiology Clinical Medicine Emergency Medicine
Endocrinology Gastroenterology Hematology/Oncology Infectious Disease Nephrology
Neurology/Neurosurgery Obstetrics/Gynecology Pediatrics Pulmonary/Critical Care View All
Specialties TOPICS AI in Medicine Climate Crisis and Health Coronavirus Fundamentals of Health …
Medicine Skip to main content The New England Journal of Medicine homepage Advanced
Search SEARCH SPECIALTIES Cardiology Clinical Medicine Emergency Medicine
Endocrinology Gastroenterology Hematology/Oncology Infectious Disease Nephrology
Neurology/Neurosurgery Obstetrics/Gynecology Pediatrics Pulmonary/Critical Care View All
Specialties TOPICS AI in Medicine Climate Crisis and Health Coronavirus Fundamentals of Health …
In a survey of the spectrum of mutational burdens in 27 types of cancers, there was a correlation between an increased mutational burden and the response to checkpoint inhibition of PD-1 and PD-L1.
![](/scholar/images/qa_favicons/nejm.org.png)